NCT03324776View on ClinicalTrials.gov

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

June 10, 2020

Study Completion Date

June 10, 2020

Conditions
Type2 Diabetes
Interventions
DRUG

Afrezza Inhalant Product

Mealtime Ultra-Rapid Acting Insulin

Trial Locations (1)

21204

MODEL Clinical Research, Baltimore

Sponsors

Collaborators (1)

Mannkind Corporation
All Listed Sponsors
collaborator

Mannkind Corporation

INDUSTRY

lead

Model Clinical Research LLC

OTHER

NCT03324776 - Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients | Biotech Hunter | Biotech Hunter